Arcus Biosciences, Inc. (RCUS)
USD 15.17
(-5.66%)
USD 15.17
(-5.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -283 Million USD | -10.23% |
| 2022 | -250 Million USD | -580.83% |
| 2021 | 61.96 Million USD | 143.98% |
| 2020 | -118.46 Million USD | -40.74% |
| 2019 | -81.13 Million USD | -58.16% |
| 2018 | -51.19 Million USD | -10.35% |
| 2017 | -50.82 Million USD | -201.33% |
| 2016 | -16.86 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -104 Million USD | 0.0% |
| 2024 Q1 | 20 Million USD | 100.0% |
| 2023 Q2 | -74 Million USD | 3.9% |
| 2023 FY | - USD | -10.23% |
| 2023 Q1 | -77 Million USD | -16.67% |
| 2023 Q3 | -68 Million USD | 8.11% |
| 2023 Q4 | -77 Million USD | -13.24% |
| 2022 Q2 | -64.61 Million USD | 0.81% |
| 2022 Q4 | -66 Million USD | -5.06% |
| 2022 FY | - USD | -580.83% |
| 2022 Q1 | -65.14 Million USD | -123.15% |
| 2022 Q3 | -62.82 Million USD | 2.77% |
| 2021 Q1 | -71.4 Million USD | -37.29% |
| 2021 FY | - USD | 143.98% |
| 2021 Q2 | -74.73 Million USD | -4.66% |
| 2021 Q4 | 281.44 Million USD | 467.47% |
| 2021 Q3 | -76.58 Million USD | -2.48% |
| 2020 FY | - USD | -40.74% |
| 2020 Q1 | -28.04 Million USD | -59.98% |
| 2020 Q2 | -44.71 Million USD | -59.48% |
| 2020 Q3 | 2.29 Million USD | 105.13% |
| 2020 Q4 | -52.01 Million USD | -2367.31% |
| 2019 Q4 | -17.52 Million USD | 21.63% |
| 2019 Q3 | -22.36 Million USD | 20.91% |
| 2019 Q2 | -28.27 Million USD | -58.68% |
| 2019 Q1 | -17.82 Million USD | -32.16% |
| 2019 FY | - USD | -58.16% |
| 2018 Q3 | -11.17 Million USD | 25.45% |
| 2018 FY | - USD | -10.35% |
| 2018 Q2 | -14.98 Million USD | -19.84% |
| 2018 Q1 | -12.5 Million USD | 0.6% |
| 2018 Q4 | -13.48 Million USD | -20.71% |
| 2017 Q1 | -6.81 Million USD | 0.0% |
| 2017 FY | - USD | -201.33% |
| 2017 Q4 | -12.57 Million USD | 43.85% |
| 2017 Q3 | -22.4 Million USD | -147.92% |
| 2017 Q2 | -9.03 Million USD | -32.61% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ADC Therapeutics SA | -146.76 Million USD | -92.829% |
| Alto Neuroscience, Inc. | -34.56 Million USD | -718.818% |
| Annovis Bio, Inc. | -45.03 Million USD | -528.4% |
| Biohaven Pharmaceutical Holding Company Ltd. | -429.13 Million USD | 34.054% |
| Ginkgo Bioworks Holdings, Inc. | -821.29 Million USD | 65.542% |
| Nuvation Bio Inc. | -99.6 Million USD | -184.137% |
| Nuvation Bio Inc. | -99.6 Million USD | -184.137% |
| Theriva Biologics, Inc. | -19.85 Million USD | -1325.405% |
| Zymeworks Inc. | -129.95 Million USD | -117.766% |